GlyTherix Ltd. (AU)

https://www.glytherix.com

GlyTherix Ltd is an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid tumours. Miltuximab specifically targets Glypican-1, a protein found in solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue. The company has a strong proprietary and Intellectual Property position covering both Miltuximab and the antigen Glypican-1. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope. GlyTherix has completed a ‘First-in-Human’ trial of 12 patients using Miltuximab with no drug-related adverse events. Miltuximab will be used in a Phase Ib trial as an antibody theranostic. GlyTherix is interested in partnerships or collaborations with larger biotech and pharmaceutical partners. *

	Start	2022-12-19 existent
	Industry	theranostics (Tx)
	Industry 2	RADIOPHARMACEUTICAL (RPT)
	Person	Walsh, Brad (GlyTherix 202212 CEO)

	City	n. a. Sydney NSW
		Address record changed: 2025-01-17

Basic data	Employees	n. a.

		* Document for »About Section«: Eckert & Ziegler SE. (1/13/25). "Press Release: Eckert & Ziegler and GlyTherix Extend Collaboration with Actinium-225 Supply Agreement". Berlin & Sydney.

		Record changed: 2025-01-17

Picture Berlin Partner Portrait Bio:cap Investival for You 650x200px

More documents for GlyTherix Ltd. (AU)

[1] Adcendo ApS. (12/19/22). "Press Release: GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)